Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

This study aims to describe an association between the Pfizer-BioNTech (BNT162b2) vaccine and decreased risk of symptomatic and asymptomatic infections with SARS-CoV-2 in hospital employees.

Automated summary

The study demonstrates an association between the Pfizer-BioNTech vaccine and decreased risk of symptomatic and asymptomatic infections with SARS-CoV-2 in hospital employees.